Answers are grounded in this paper and cite their sources.
Much has been reported on the benefits of saline, adenine, glucose and mannitol (SAGM) preserved satellite aliquots for neonatal small volume transfusion (SVT). First, the infant receives the same donor for several (in most blood banks, four) transfusions, reducing the risk of adverse reaction. Second, the minute volumes transfused to extremely low birth weight infants make this an effective way of conserving blood stocks. Third, it is cost-effective.1-3 However, SAGM blood is not generally advocated for neonatal large volume transfusion (LVT) secondary to concerns regarding potential toxicity of these additives in large volumes.4-6 However, increasingly, concerns regarding the safety of CPD (citrate, phosphate and dextrose) additive blood are making it the choice in a number of UK centers.7 On the basis of an audit we carried out, we wish to highlight that SAGM blood used in neonatal LVT would likely result in significant donor exposure reduction, thus blood stock savings. We performed a retrospective analysis of red cell transfusions at a quaternary neonatal unit acting as a referral point for infants requiring cardiothoracic, general surgical and extracorporeal life support (ECLS) procedures from 1 January to 31 December 2004. This occurred in deference to anecdotal suggestions that the department had a low rate of SAGM aliquot usage, and we sought to establish why. We determined the number of SAGM aliquots and non-SAGM CPD units transfused per infant according to gestation, birth weight and reason for transfusion. We then assessed how many patients were given a small volume transfusion within 35 days of a CPD transfusion. Since exchange transfusion (ET) requires a specific preparation of packed red cells,8 the one infant requiring this was excluded. Eighty-two infants were transfused over the study period. Forty-four percent (n = 36) were term (> 35 weeks). Forty-two percent (n = 35) of infants transfused underwent LVT (i.e. cardiac bypass or ECLS). The remaining infant underwent ET. Fourteen infants underwent procedures during cardiopulmonary bypass (CPBy) and eight experienced ECLS. All infants were term and with a birth weight of greater than 2.0 kg, given that only such infants undergo these procedures at our center. The remainder (n = 13) were transfused during general surgical procedures (including congenital diaphragmatic hernia, gastroschisis, small bowel atresia and necrotising enterocolitis repairs). Eighty-eight percent of all units used were CPD, in deference to the high number of units used for LVT. We did not assess volumes of blood used for transfusion since, in bypass and ECLS, this is partly dependent on technical factors such as pump priming preferences. Each CPD unit at our institute has a volume of approximately 250 mL. A mean of 8.6 units were given to infants who experienced ECLS (r: 5–37), 2.1 units (r: 1–4) for those who underwent CPBy, and 1.84 for infants who had general surgery (r: 1–4). The average duration of ECLS was 6.8 days (r: 1–14). Sixty-nine percent of infants transfused with CPD units required at least one further small volume transfusion within 35 days. As such, most were transfused with a mix of CPD and SAGM units throughout their admission, and had a high donor exposure (DE) rate. DE rates for the 35-day period from LVT were higher for those experiencing ECMO than CPBy (17, r: 5–39 vs. 4.6, r: 2–14). No adverse transfusion reactions were noted. The use of SAGM blood for LVT in our patients would potentially have reduced DE to as low as five for infants undergoing ECLS and two for CPBy. Unused units would be returned to the blood bank and reissued to other children. Rosenberg et al. describe similar protocols in their methods of reducing DE by using single-donor platelet and fresh frozen plasma aliquots.9 No studies could be found assessing DE with SAGM versus CPD blood in LVT. A case report by Win et al.10 did however note the use of SAGM blood for neonatal ET, without any adverse effects (although renal function was closely monitored). Of note, two pertinent studies were found regarding a lower pump priming volume for neonatal ECLS, but the effect on DE was not noted.11, 12 Given that it is not yet national or local policy to routinely use SAGM additive blood for LVT, an alternate option could be to split CPD additive blood into smaller packs valid for up to 28 days for both SVT and LVT.13 Since staff routinely requested CPD units at our center, some extremely premature infants had been transfused single CPD units for SVT. As such, we composed a guideline to remind staff at our center to use SAGM red cells for SVT in infants less than 30 weeks gestation. Naturally, any infant anticipated to require multiple transfusions would usurp this guideline regardless of weight or gestation. In conclusion, a large proportion of infants admitted to quaternary neonatal units for LVT require repeat SVTs within a 35-day period thereafter. Further prospective studies are required to support the use of SAGM blood for LVT to reduce donor exposures and blood stock wastage in this important neonatal group.
No takes yet. Share an insight, caveat, or question.
Beattie et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: